With the likely approval of Eli Lilly’s new weight loss pill, orforglipron, coming this quarter, a top executive said that the pharma is prepared to meet expected demand.
In November, orforglipron was granted an FDA priority voucher, cutting its review time to as little as one to two months from 10-12 months for standard review. Lilly submitted an application to the FDA for the drug in December.
“We intend to launch in many, many countries around the world, as quickly as possible,” Daniel Skovronsky, the company chief scientific and medical officer, told Reuters, adding the company has spent “tens of billions of dollars” on new facilities to manufacture it.
The starting dose strength of orforglipron for cash pay customers is $149 a months, though higher strengths would push the price to as high at $399 monthly.
Assuming approval, orforglipron will face competition right off the bat. Novo Nordisk (NVO) launched the pill version of its obesity drug Wegovy earlier in January with the same cash price as orforglipron for starting doses.
